Ivonescimab: The Two Pronged Attack

Abstract

Targeted therapy and immunotherapy have changed the landscape of treatment of cancers with respect to longevity and quality of life. Programmed death 1 (PD-1) and vascular endothelial growth factor (VEGF) are very salient targets of anticancer drugs. Dual blockade with bispecific antibodies is a novel mode of treatment of malignancies, which has already been successful in hematological malignancies. Ivonescimab, a novel bispecific antibody that targets PD-1 and VEGF, has been developed in China. It has been found to be beneficial in nonsmall cell lung cancer, biliary tract cancers, and breast cancers for which phase 3 clinical trials have already been discussed in various meetings and publications. The current drug review is regarding the parameters of this novel drug—the mechanism of action, clinical and preclinical trials, and approvals.

Keywords

ivonescimab - VEGF - PD-1 - targeted therapy - immunotherapy

Publication History

Article published online:
11 June 2025

• References

• 1 Desai A, Reddy NK, Subbiah V. Top advances of the year: precision oncology. Cancer 2023; 129 (11) 1634-1642
• 2 Dhillon S. Ivonescimab: first approval. Drugs 2024; 84 (09) 1135-1142
• 3 Zhong T, Huang Z, Pang X. et al. 1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects. J Immunother Cancer 2023; 11: x
• 4 Fang W, Zhao Y, Luo Y. et al; HARMONi-A Study Investigators. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 2024; 332 (07) 561-570
• 5 Zhou C. Phase 3 study of ivonescimab (AK112) vs pembrolizumab as first-line treatment for PD-L1–positive advanced NSCLC: primary analysis of HARMONi-2. Paper presented at: World Conference on Lung Cancer, 2024; September 8, 2024; San Diego
• 6 Frentzas S, Austria Mislang AR, Lemech C. et al. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer 2024; 12 (04) e008037
• 7 Zhao Y, Chen G, Chen J. et al. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 2023; 62: 102106
• 8 Xiong A, Wang L, Chen J. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 2025; 405 (10481): 839-849
• 9 Ouyang Q, Wang X, Tian C. et al. The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC). Ann Oncol 2024; 35: S360-S361
• 10 Ivonescimab in combination with chemotherapy approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A clinical trial: positive trend observed in overall survival towards ivonescimab plus chemotherapy; media release; PR Newswire. Published June 1, 2024. Accessed April 30, 2025 at: https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html
• 11 Ivonescimab receives NMPA approval for first-line treatment of PD-L1-positive NSCLC, based on breakthrough head to head phase III trial demonstrating superior efficacy over pembrolizumab. News release; PR Newswire. Published April 25, 2025. Accessed April 30, 2025 at: https://www.prnewswire.com/news-releases/ivonescimab-receives-nmpa-approval-for-first-line-treatment-of-pd-l1-positive-nsclc-based-on-breakthrough-head-to-head-phase-iii-trial-demonstrating-superior-efficacy-over-pembrolizumab-302438600.html
• 12 Oncology Drugs Fast-Tracked by the FDA in October 2024; media release, Oncology news central, Published November 1, 2024. Accessed April 30, 2025 at: https://www.oncologynewscentral.com/article/oncology-drugs-fast-tracked-by-the-fda-in-october-2024